Manageability and Safety Assessment of Sepraspray in Abdominal Surgery.

Manageability and Safety Assessment of the SepraSpray Anti-adhesion Barrier in Abdominal Coelioscopic Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00813397

Acronym

C-MUST

Enrollment

210

Registered

2008-12-23

Start date

2008-09-30

Completion date

2009-07-31

Last updated

2015-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesion Prevention

Brief summary

This study will examine the performance of SeprasSpray in patients undergoing abdominal surgery (laparoscopic).

Interventions

DEVICESepraspray

Max. 10g of Sepraspray

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients 18 years old and over that require laparoscopic abdominal surgery

Exclusion criteria

* Patients who are pregnant or have an ongoing infectious complications from a previous surgery

Design outcomes

Primary

Measure	Time frame
Morbidity	30 days

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026